Contribution
My Lords, I start by congratulating the Government on their commitment to improving outcomes for patients. I particularly congratulate the maiden speakers on their absolutely wonderful contributions. I look forward to hearing the others to come.
I welcome wholeheartedly the proposal for a single patient record. Many people with cancer, particularly those who have faced lengthy diagnostic journeys, will benefit from no longer having to repeat and explain their history again and again to different professionals. Many patients believe that we have one already—or cannot believe, in this day and age, that we have not. We need to tackle the safeguards, but we really need to crack on with this.
Following the 2012 reforms, I was incredibly disappointed to see the disbanding of the cancer networks. Those were a collection of bodies that were set up to deliver the first NHS cancer plan, which was published in 2000. They became very strong. I will focus on three issues relating to the Bill that are of great importance to cancer patients.
First, we need to protect cancer services during the transition; we need to ensure that cancer outcomes remain a national priority; and we must continue to work on unlocking faster clinical trials. As the members of the One Cancer Voice charity coalition have argued, it is essential that the functions required to deliver the recently agreed and widely welcomed cancer plan are protected through this transition. The plan is extremely ambitious. There are more than 100 recommendations, and its success depends on effective national leadership, accountability and strong delivery. This matters, particularly to people with rare and less common cancers, where progress has often been slower.
Key functions and delivery that must be protected include, for example, the collection of robust data around metastatic cancers, research infrastructure, national oversight programmes such as for screening, and the capacity to commission vital highly specialised services. There is a tension—and we have to be realistic about this—between neighbourhood health services and the need for cancer patients to access extremely specialist services. There must be full integration so that patients can continue to receive the expert support they need. I hope the Minister can assure me and the House that cancer services, specialist commissioning, screening programmes and research infrastructure will be protected through this Bill.
I would like to ask about the future of the measure in the Health and Care Act 2022 where the mandate was established. As part of the mandate, there was a commitment to focus on monitoring cancer outcomes. The mandate will disappear and we do not know what will happen or what will replace it. I am concerned to know what will replace the mandate and how cancer outcomes will be expressed in that process.
The last thing I want to talk about, very quickly, is the importance of research in the NHS. For example, we know that clinical research has transformed outcomes for cancer patients over recent years. We have seen improvements in survival and quality of life. A thriving clinical trial environment is vital to this, to our life sciences sector and to improving outcomes for patients as we go forward. The Government’s ambition to reduce clinical trials set-up times needs to be carefully thought through here. Can we ensure that that ambition is applied to non-commercial trials as well as to commercial trials, where there appears to be much progress being made? Some 95% of participants in clinical trials are in trials being led by charities and the NHS, which are non-commercial.
I look for these reassurances from the Minister: that the cancer plan will remain on track, that we will see how improving outcomes will be maintained within whatever the replacement for the mandate will be, and that patients will continue to see faster improvement in access to clinical trials and innovation, including those for less common cancers.